ATC Group: L01FX21 Naxitamab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FX21 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FX Other monoclonal antibodies
5 L01FX21

Active ingredients in L01FX21

Active Ingredient

Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).

Related product monographs

Document Type Information Source  
 DANYELZA Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Israel (IL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.